PD-1 inhibitors have shown clinical benefits in only a subset of hepatocellular carcinoma (HCC) patients, while most exhibit primary resistance or rapidly develop acquired resistance (7). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.